Sets new standards for epilepsy treatment with Iracet

Durrant Pate/Contributor

Epilepsy care in Jamaica is being revolutionized by local health care provider, RA Williams Distributors with the introduction of Iracet, the first generic Levetiracetam available in the island.

Iracet, a play on the drug name LevetIRACETam, which provides an affordable alternative to the costly brand-name version, making epilepsy treatment more accessible. Essential for managing seizures, Levetiracetam is FDA-approved but often financially out of reach for many Jamaicans. 

Manufactured by Square Pharmaceuticals, a global leader in high-quality, affordable medications, Iracet delivers a safe and effective solution for treating epilepsy, including post-stroke seizures. With an excellent safety profile, especially for women who are pregnant or planning to conceive, Iracet offers a safe and affordable treatment option for those who have struggled to access effective epilepsy care. 

Now covered by all major health insurance schemes, including the NHF, Iracet’s availability makes it an accessible solution for patients across Jamaica, improving quality of life and providing a reliable option for managing their condition.

RA Williams exclusive distributor

As the exclusive distributor of Iracet in Jamaica, RA Williams continues its commitment to providing high-quality healthcare solutions to the Jamaican people. With over 12 years of experience in the industry, RA Williams is partnering with Square Pharmaceuticals in bringing the pharmaceutical to Jamaica.

At Sunday’s launch, CEO of RA Williams Distributors Audley Reid highlighted, “for the past decade, this partnership with Square Pharmaceuticals has been built on a shared commitment to improving the lives of those we serve. The introduction of Iracet is more than just a product introduction. It is a celebration of progress, accessibility, and hope for countless Jamaicans affected by epilepsy. By making this medication affordable, we are addressing critical health issues while equipping families with the tools they need to improve their quality of life.”

She said the company’s role in introducing Iracet reinforces RA Williams’ reputation as a leader in healthcare distribution, ensuring that patients in Jamaica have access to the latest advancements in medical treatment.

Chairperson of the Pharmacy Council of Jamaica, Dr Ernestine Watson who also spoke at the launch endorsed the life-changing treatment during her keynote address shared, “Iracet is not metabolised in the liver, meaning it won’t interact with other medications the patient may be taking, thus avoiding dangerous complications. Unlike some other anti-epileptic drugs, Iracet doesn’t cause side effects like changes in facial shape, gum thickening, serious rashes, excessive nausea, or bleeding.” 

She said the drug can be used in a wide range of scenarios, from childhood epilepsy to older patients, and even as an adjunct therapy for those who need additional support.

Tamara Melville-Scott, Country Manager at Square Pharmaceuticals highlighted in her address said, “Iracet stands out for its unique safety profile, which includes a low potential for drug-drug interactions, making it an excellent option for patients with complex health conditions, such as those on anti-coagulants, statins, or oral contraceptives. Most importantly, it is safe for pregnant patients and women of reproductive age, offering both practitioners and patients peace of mind when managing epilepsy treatment.”